What is BrainsWay?
Founded in 2003 and headquartered in Jerusalem, Israel, BrainsWay is a global leader in advanced noninvasive neurostimulation treatments. The company leverages its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology, developed in collaboration with the National Institute of Health. BrainsWay holds the distinction of being the first and only TMS company with three FDA-cleared indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Its technology also shows promise for treating bipolar disorders, PTSD, schizophrenia, chronic pain, and other neurological and psychiatric conditions, serving medical professionals and institutions across the United States, East Asia, and internationally. The company is publicly traded on both the NASDAQ and Tel Aviv Stock Exchange.
How much funding has BrainsWay raised?
BrainsWay has raised a total of $20M across 1 funding round:
Stock/Share Issuance
$20M
Stock/Share Issuance (2025): $20M, investors not publicly disclosed
What's next for BrainsWay?
The substantial enterprise-level funding and recent strategic investment indicate a strong growth trajectory for BrainsWay. This capital infusion is expected to fuel further research and development, potentially expanding the therapeutic applications of its Deep TMS platform. Strategic backing suggests an emphasis on market penetration and scaling operations, likely targeting broader adoption in psychiatric and neurological treatment centers globally. Continued focus on securing regulatory clearances and demonstrating clinical efficacy will be paramount for sustained expansion and market leadership in the competitive neurotechnology sector.
See full BrainsWay company page
